B-type natriuretic peptide increases cortisol and catecholamine concentrations in healthy subjects

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

B-type natriuretic peptide (BNP) is a hormone released by the heart in response to volume load and exerts natriuretic properties.

Here the researchers investigate the changes in pituitary, adrenal, and thyroid hormones in response to BNP administration in a randomized single-blinded crossover study conducted in ten healthy men aged 21-29 yr.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether BNP (Nesiritide) was given.

The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.

Each person switched between BNP (Nesiritide) and the comparison at some point, usually with a gap in between.

Circulating concentrations of pituitary, adrenal, and thyroid hormones, heart rate, and blood pressure were measured at baseline and hourly afterwards.

What Was Measured

The subject headings attached to it are Adrenal Glands, Blood Pressure, Catecholamines, Epinephrine, Healthy Volunteers, Heart Rate and Hydrocortisone.

Author keywords: BNP, adrenergic activity, cortisol, natriuretic peptides, neuroendocrine activation and pituitary.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of BNP (Nesiritide).

The publication is from 2017 (Journal of applied physiology (Bethesda, Md. : 1985)), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.